Finalized Federal Rule Reshapes Medicaid Coverage for Gender-Affirming Care for Minors
CMS Finalizes Rule on Gender-affirming Medical Care
The Centers for Medicare & Medicaid Services (CMS) has finalized a rule barring federal Medicaid and Children’s Health Insurance Program (CHIP) dollars from paying for certain gender-affirming medical care for minors, marking a significant shift in federal health policy with direct implications for physicians who care for transgender youth.
The rule was finalized on August 11 and covers certain pharmaceutical and surgical interventions intended to alter a patient’s physical characteristics to align with a gender identity different from their sex.
What Physicians Should Know
- The policy takes effect on October 13, 2026, and applies to federal Medicaid funding for patients under 18 and federal CHIP funding for patients under 19.
- It does not prohibit states from using their own funds to cover the services, meaning the practical impact will vary depending on how individual states respond.
- For patients already receiving hormone therapy, CMS is allowing federal funding to continue for a tapering period of up to six months after the rule takes effect.
Where Proponents & Opponents Stand on the Rule
The administration argues the policy is necessary to protect children and ensure taxpayer-funded programs support treatments it considers sufficiently supported by evidence. Supporters of the rule have emphasized concerns about the long-term and potentially irreversible effects of some interventions, while opponents have argued that decisions about gender dysphoria treatment should remain between patients, families and their clinicians and warn that restricting coverage could disrupt established care.
